Microbial-Based Cancer Therapies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (15 September 2022) | Viewed by 10449
Special Issue Editors
Interests: microbial-based cancer therapies (MBCTs); tumor microbiome; immune-reconstituted patient-derived xenograft (AIR-PDX) mouse models; cancer immuno-nanoparticles
Interests: immune system; tumor microenvironment; engaging host immune responses with novel approaches to eliminate cancer
Special Issue Information
Dear Colleagues,
Microbial-based cancer therapies (MBCTs) have been shown to augment anti-tumor immune responses and improve long-term clinical outcomes. Although reported successes extend across millennia and involve a spectrum of microbial species, the number of MBCTs that have been granted federal approval remain limited. Thus, there is great need for expanding awareness regarding MBCTs. Thus far, major mechanisms involve 1) debulking of the cancer via preferential tumor cell (versus normal cell) lysis by oncolytic pathogens and 2) conversion of the tumor microenvironment from “cold” (immune response-preventing) to “hot” (anti-tumor immunity-augmenting) by oncolytic and non-oncolytic pathogens, both active and inactivated. However, much more is to be gained from further studies and, thus, the need for a Special Issue covering the spectrum of MBCT-related discoveries from basic mechanisms to translational avenues, case studies, and clinical successes as an innovative means of improving and saving the lives of patients with cancer.
Dr. Andrew Zloza
Dr. Amanda L. Marzo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- immunotherapy
- tumor
- immuno-oncology
- microbial-based cancer therapies (MBCTs)
- tumor microbiome
- virus
- viral
- bacteria
- bacterial
- oncolytic
- non-oncolytic